Novartis AG has reached an agreement for exclusive global (excluding South Korea) development and commercialization rights to Chong Kun Dang Pharmaceutical Corp.'s (CKD) CKD-510, a selective, non-hydroxamate small molecule histone deacetylase 6 (HDAC6) inhibitor, in a deal worth up to $1.3bn.
Novartis Bags Chong Kun Dang’s HDAC6 Inhibitor In $1.3bn Deal
Potential In Cardiovascular Indications
The deal marks the biggest out-licensing agreement ever for Chong Kun Dang, with the Swiss giant poised to explore the novel small molecule in various cardiovascular indications.
More from Business
• By
Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
More from Scrip
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.